Identification and characterization of stressed degradation products of prulifloxacin using LC-ESI-MS/Q-TOF, MSn experiments: Development of a validated specific stability-indicating LC-MS method

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 3, 2011, Pages 560-568

  Raju, B ^a   Ramesh, M ^a   Srinivas, R ^a   Raju, S Satyanarayana ^a   Venkateswarlu, Y ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Accurate mass measurements; Degradation products; LC ESI MS; Prulifloxacin; Tandem mass spectrometry

Indexed keywords

PRULIFLOXACIN;

ARTICLE; DRUG DEGRADATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MASS SPECTROMETRY; OXIDATION; PHOTOLYSIS; PRIORITY JOURNAL; QUADRUPOLE TIME OF FLIGHT ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; TEMPERATURE STRESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIOXOLANES; DRUG STABILITY; FLUOROQUINOLONES; HYDROLYSIS; OXIDATION-REDUCTION; PHOTOLYSIS; PIPERAZINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 79961127509     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.06.021     Document Type: Article

References (22)

1. ICH Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization 2003.
2. WHO Draft Stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Products 2007, World Health Organization, Geneva.
3. CPMP Note for Guidance on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products, Committee for Proprietary Medicinal Products 2002, EMEA, London.
4. TPD Guidance for Industry Stability Testing of Existing Drug Substances and Products, Therapeutic Products Directorate 2003, Health Canada, Ottawa, ON.
5. Gorog S. The importance and the challenges of impurity profiling in modern pharmaceutical analysis. TrAC 2006, 25:755-757.
6. Murakami T., Kawasaki T., Takemura A., Fukutsu N., Kishi N., Kusu F. Identification of degradation products in loxoprofen sodium adhesive tapes by liquid chromatography-mass spectrometry and dynamic pressurized liquid extraction-solid-phase extraction coupled to liquid chromatography-nuclear magnetic resonance spectroscopy. J. Chromatogr. A 2008, 1208:164-174.
7. Novak P., Tepes P., Ilijas M., Fistric I., Bratos I., Avdagic A., Hamersak Z., Markovic V.G., Dumic M. LC-NMR and LC-MS identification of an impurity in a novel antifungal drug icofungipen. J. Pharm. Biomed. Anal. 2009, 50:68-72.
8. Murakami T., Fukutsu N., Kondo J., Kawasaki T. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. J. Chromatogr. A 2008, 1181:67-76.
9. Dev R.V., Kiran G.S.U., Subbaiah B.V., Babu B.S., Babu J.M., Dubey P.K., Vyas K. Identification of degradation products in stressed tablets of rabeprazole sodium by HPLC-hyphenated techniques. Magn. Reson. Chem. 2009, 47:443-448.
10. Shah R.P., Kumar V., Singh S. Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun. Mass Spectrom. 2008, 22:613-622.
11. Ying liu Z., Hai Zhang H., Jun Chen X., Ni Zhou X., Wan L., Liang Sun Z. Structural elucidation of degradation products of olaquindox under stressed conditions by accurate mass measurements using electrospray ionization hybrid ion-trap/time-of-flight mass spectrometry. Int. J. Mass Spectrom. 2011, 303:92-96.
12. Yoshida T., Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob. Agents Chemother. 1993, 37:793-800.
13. Jun W., Zhenyu Z., Zhanying H., Yiwen W., Yan F., Mei L., Guarang F., Yutain W. Determination of the active metabolite of prulifloxacin in human plasma by HPLC with fluorescence detection. Chromatographia 2007, 66:37-41.
14. Keam S.J., Perry C.M. Prulifloxacin. Drugs 2004, 64:2221-2234.
15. Matera M.G. Pharmacologic characteristics of prulifloxacin. Pulm. Pharmacol. Ther. 2006, 19:20-29.
16. Tougou K., Nakamura A., Watanabe S., Okuyama Y., Morino A. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos. 1998, 26:355-359.
17. Okuyama Y., Momota K., Morino A. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Arzneimittelschung 1997, 47:276-278.
18. Lingli Z., Jun W., Yaju P., Zhen L., Guorong F., Yutian W. Determination of ulifloxacin, the active metabolite of Prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 872:172-176.
19. Wang X.L., Li A.Y., Zhao H.C., Jin L.P. Lanthanide sensitized chemiluminescences method of flow-injection for the determination of ulifloxacin and prulifloxacin. J. Anal. Chem. 2009, 64:75-81.
20. Zhongju Y., Xiaoli W., Weidong Q., Huichun Z. Capillary electrophoresis-chemiluminescences determination of norfloxacin and prulifloxacin. Anal. Chim. Acta 2008, 623:231-237.
21. Dewani A.P., Daulatkar V.J., Barik B.B., Chandewar A.V., Kanungo S.K. A validated stability-indicating HPLC method for the determination of prulifloxacin in bulk and tablet dosage form. J. Pharm. Res. 2010, 3:2574-2577.
22. Guo L., Qi M., Jin X., Wang P., Zhao H. Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2006, 832:280-285.